Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Special Survey on Parkinson's Disease Patients Treated Long-term Use of Pramipexole

10. juni 2014 opdateret af: Boehringer Ingelheim

Pramipexole Special Survey on Long-Term Use

The survey is conducted to collect safety and effectiveness information on the use of Pramipexole for long time of period in daily clinical settings in Japan.

Studieoversigt

Status

Afsluttet

Betingelser

Undersøgelsestype

Observationel

Tilmelding (Faktiske)

1645

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Japan
      • Agano, Japan
        • Boehringer Ingelheim Investigational Site
      • Aizuwakamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Akashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Akita, Japan
        • Boehringer Ingelheim Investigational Site
      • Asahikawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Asakura, Japan
        • Boehringer Ingelheim Investigational Site
      • Ayagawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Azumino, Japan
        • Boehringer Ingelheim Investigational Site
      • Bando, Japan
        • Boehringer Ingelheim Investigational Site
      • Beppu, Japan
        • Boehringer Ingelheim Investigational Site
      • Bihoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Chiba, Japan
        • Boehringer Ingelheim Investigational Site
      • Chikusei, Japan
        • Boehringer Ingelheim Investigational Site
      • Chuo, Japan
        • Boehringer Ingelheim Investigational Site
      • Date, Japan
        • Boehringer Ingelheim Investigational Site
      • Ebetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ebina, Japan
        • Boehringer Ingelheim Investigational Site
      • Eiheiji, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuchu, Japan
        • Boehringer Ingelheim Investigational Site
      • Fuji, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujieda, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujisawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Fujiyoshida, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukaya, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukui, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Fukuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Geisei, Japan
        • Boehringer Ingelheim Investigational Site
      • Gifu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ginowan, Japan
        • Boehringer Ingelheim Investigational Site
      • Hachinohe, Japan
        • Boehringer Ingelheim Investigational Site
      • Hadano, Japan
        • Boehringer Ingelheim Investigational Site
      • Haebaru, Japan
        • Boehringer Ingelheim Investigational Site
      • Hagahama, Japan
        • Boehringer Ingelheim Investigational Site
      • Hakodate, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamada, Japan
        • Boehringer Ingelheim Investigational Site
      • Hamamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Hayashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashimurayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiosaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Higashiyamato, Japan
        • Boehringer Ingelheim Investigational Site
      • Himeji, Japan
        • Boehringer Ingelheim Investigational Site
      • Hiratsuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Hirosaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Hiroshima, Japan
        • Boehringer Ingelheim Investigational Site
      • Hita, Japan
        • Boehringer Ingelheim Investigational Site
      • Hofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ibaragi, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichikikushikino, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Ichinoseki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iizuka, Japan
        • Boehringer Ingelheim Investigational Site
      • Ikeda, Japan
        • Boehringer Ingelheim Investigational Site
      • Ikoma, Japan
        • Boehringer Ingelheim Investigational Site
      • Ina, Japan
        • Boehringer Ingelheim Investigational Site
      • Inazawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Inba, Japan
        • Boehringer Ingelheim Investigational Site
      • Inuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Isezaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Itoigawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Iwata, Japan
        • Boehringer Ingelheim Investigational Site
      • Joetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kagoshima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kahoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Kajiki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kakegawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kakogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamisu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kamogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kanazawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kannonji, Japan
        • Boehringer Ingelheim Investigational Site
      • Karatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashiwa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kashiwazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kasukabe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kato, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawagoe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kawatana, Japan
        • Boehringer Ingelheim Investigational Site
      • Kikugawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kirishima, Japan
        • Boehringer Ingelheim Investigational Site
      • Kitakyushu, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyose, Japan
        • Boehringer Ingelheim Investigational Site
      • Kiyotake, Japan
        • Boehringer Ingelheim Investigational Site
      • Kizugawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kobayashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kobe, Japan
        • Boehringer Ingelheim Investigational Site
      • Kochi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kodaira, Japan
        • Boehringer Ingelheim Investigational Site
      • Kofu, Japan
        • Boehringer Ingelheim Investigational Site
      • Koga, Japan
        • Boehringer Ingelheim Investigational Site
      • Kokubunji, Japan
        • Boehringer Ingelheim Investigational Site
      • Komae, Japan
        • Boehringer Ingelheim Investigational Site
      • Komatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Komoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Koriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Koshi, Japan
        • Boehringer Ingelheim Investigational Site
      • Koshigawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Kumamoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurashiki, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurayoshi, Japan
        • Boehringer Ingelheim Investigational Site
      • Kure, Japan
        • Boehringer Ingelheim Investigational Site
      • Kurume, Japan
        • Boehringer Ingelheim Investigational Site
      • Kushiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Kutchan, Japan
        • Boehringer Ingelheim Investigational Site
      • Kuwana, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyonan, Japan
        • Boehringer Ingelheim Investigational Site
      • Kyoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Maebaru, Japan
        • Boehringer Ingelheim Investigational Site
      • Maebashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Maibara, Japan
        • Boehringer Ingelheim Investigational Site
      • Maizuru, Japan
        • Boehringer Ingelheim Investigational Site
      • Marugame, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsuda, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsudo, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsue, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsumoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Matsuyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Mibu, Japan
        • Boehringer Ingelheim Investigational Site
      • Mihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Miki, Japan
        • Boehringer Ingelheim Investigational Site
      • Minakami, Japan
        • Boehringer Ingelheim Investigational Site
      • Minamata, Japan
        • Boehringer Ingelheim Investigational Site
      • Minobu, Japan
        • Boehringer Ingelheim Investigational Site
      • Misashino, Japan
        • Boehringer Ingelheim Investigational Site
      • Mito, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyakonojo, Japan
        • Boehringer Ingelheim Investigational Site
      • Miyazaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Mooka, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Morioka, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriya, Japan
        • Boehringer Ingelheim Investigational Site
      • Moriyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Muroran, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagakute, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagaokakyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Nagoya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nangoku, Japan
        • Boehringer Ingelheim Investigational Site
      • Nara, Japan
        • Boehringer Ingelheim Investigational Site
      • Narita, Japan
        • Boehringer Ingelheim Investigational Site
      • Naruto, Japan
        • Boehringer Ingelheim Investigational Site
      • Nichinan, Japan
        • Boehringer Ingelheim Investigational Site
      • Niigata, Japan
        • Boehringer Ingelheim Investigational Site
      • Niihama, Japan
        • Boehringer Ingelheim Investigational Site
      • Nikko, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishigo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishinomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishio, Japan
        • Boehringer Ingelheim Investigational Site
      • Nishitokyo, Japan
        • Boehringer Ingelheim Investigational Site
      • Nobeoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Noboribetsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Numazu, Japan
        • Boehringer Ingelheim Investigational Site
      • Obama, Japan
        • Boehringer Ingelheim Investigational Site
      • Obihiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Odate, Japan
        • Boehringer Ingelheim Investigational Site
      • Odawara, Japan
        • Boehringer Ingelheim Investigational Site
      • Ofunato, Japan
        • Boehringer Ingelheim Investigational Site
      • Ogaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Ohzu, Japan
        • Boehringer Ingelheim Investigational Site
      • Oiso, Japan
        • Boehringer Ingelheim Investigational Site
      • Oita, Japan
        • Boehringer Ingelheim Investigational Site
      • Ojiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Okawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Okayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Omaezaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Omura, Japan
        • Boehringer Ingelheim Investigational Site
      • Omuta, Japan
        • Boehringer Ingelheim Investigational Site
      • Onga, Japan
        • Boehringer Ingelheim Investigational Site
      • Onojo, Japan
        • Boehringer Ingelheim Investigational Site
      • Onomichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Osaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Otsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Ozu, Japan
        • Boehringer Ingelheim Investigational Site
      • Sado, Japan
        • Boehringer Ingelheim Investigational Site
      • Saga, Japan
        • Boehringer Ingelheim Investigational Site
      • Sagamihara, Japan
        • Boehringer Ingelheim Investigational Site
      • Saitama, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakai, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakaide, Japan
        • Boehringer Ingelheim Investigational Site
      • Sakata, Japan
        • Boehringer Ingelheim Investigational Site
      • Saku, Japan
        • Boehringer Ingelheim Investigational Site
      • Sanjo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sano, Japan
        • Boehringer Ingelheim Investigational Site
      • Sanyoonoda, Japan
        • Boehringer Ingelheim Investigational Site
      • Sapporo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sasebo, Japan
        • Boehringer Ingelheim Investigational Site
      • Seijo, Japan
        • Boehringer Ingelheim Investigational Site
      • Sendai, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimabara, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimonoseki, Japan
        • Boehringer Ingelheim Investigational Site
      • Shimotsuke, Japan
        • Boehringer Ingelheim Investigational Site
      • Shingu, Japan
        • Boehringer Ingelheim Investigational Site
      • Shinshiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Shizuoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Shunan, Japan
        • Boehringer Ingelheim Investigational Site
      • Soo, Japan
        • Boehringer Ingelheim Investigational Site
      • Suita, Japan
        • Boehringer Ingelheim Investigational Site
      • Tajimi, Japan
        • Boehringer Ingelheim Investigational Site
      • Takamatsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Takanabe, Japan
        • Boehringer Ingelheim Investigational Site
      • Takaoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Takasago, Japan
        • Boehringer Ingelheim Investigational Site
      • Takasaki, Japan
        • Boehringer Ingelheim Investigational Site
      • Takatsuki, Japan
        • Boehringer Ingelheim Investigational Site
      • Takehara, Japan
        • Boehringer Ingelheim Investigational Site
      • Toda, Japan
        • Boehringer Ingelheim Investigational Site
      • Togitsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokoname, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokushima, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Adachi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Bunkyo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Chiyoda-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Edogawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Itabashi-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Katsushika-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Kita-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Meguro-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Minayo-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nakano-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Nerima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Ota-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Setagaya-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinagawa-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Shinjuku-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Suginami-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tokyo Toshima-ku, Japan
        • Boehringer Ingelheim Investigational Site
      • Tomakomai, Japan
        • Boehringer Ingelheim Investigational Site
      • Tomiai, Japan
        • Boehringer Ingelheim Investigational Site
      • Tondabayashi, Japan
        • Boehringer Ingelheim Investigational Site
      • Toon, Japan
        • Boehringer Ingelheim Investigational Site
      • Toride, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyama, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyoake, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyokawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyonaka, Japan
        • Boehringer Ingelheim Investigational Site
      • Toyooka, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsu, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsubata, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsuchiura, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsukuba, Japan
        • Boehringer Ingelheim Investigational Site
      • Tsuruoka, Japan
        • Boehringer Ingelheim Investigational Site
      • Uchinada, Japan
        • Boehringer Ingelheim Investigational Site
      • Ueda, Japan
        • Boehringer Ingelheim Investigational Site
      • Uji, Japan
        • Boehringer Ingelheim Investigational Site
      • Ujo, Japan
        • Boehringer Ingelheim Investigational Site
      • Urayasu, Japan
        • Boehringer Ingelheim Investigational Site
      • Uruma, Japan
        • Boehringer Ingelheim Investigational Site
      • Utsunomiya, Japan
        • Boehringer Ingelheim Investigational Site
      • Wakayama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamagata, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamaguchi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yamamoto, Japan
        • Boehringer Ingelheim Investigational Site
      • Yanai, Japan
        • Boehringer Ingelheim Investigational Site
      • Yao, Japan
        • Boehringer Ingelheim Investigational Site
      • Yashiro, Japan
        • Boehringer Ingelheim Investigational Site
      • Yazu, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokkaichi, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokohama, Japan
        • Boehringer Ingelheim Investigational Site
      • Yokote, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoro, Japan
        • Boehringer Ingelheim Investigational Site
      • Yoshinogawa, Japan
        • Boehringer Ingelheim Investigational Site
      • Yufu, Japan
        • Boehringer Ingelheim Investigational Site
      • Zama, Japan
        • Boehringer Ingelheim Investigational Site

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Barn
  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Parkinson's disease patients in daily clinical settings

Beskrivelse

Inclusion Criteria:

Patients with Parkinson's disease

Exclusion Criteria:

Patients should have been treated according to the Japanese insert slip

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Proportion of Adverse Events, Adverse Drug Reactions, Serious Adverse Events
Tidsramme: during 18 months
The aim of this Post Marketing Surveillance (PMS) was to obtain long-term safety data with treatment of pramipexole in Parkinson's disease (PD) patients. Therefore these items were considered as a safety evaluation.
during 18 months

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Clinical Global Impression of Improvement
Tidsramme: 18 months
Investigators evaluation of the PD symptoms on a rating scale of 5 categories (very much improved, much improved, minimally improved, no effect, and unassessable).
18 months
Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Part III Total Score
Tidsramme: Baseline and at 18 months (or at the time of discontinuation)
Motor examination is assessed by 27 questionnaire items in UPDRS Part III section. Each item is scored from 0 (best) to 4 (worst), and the total score of UPDRS Part III is from 0 (best) to 108 (worst). A decrease in the score means improvement.
Baseline and at 18 months (or at the time of discontinuation)
Change From Baseline in Modified Hoehn & Yahr Rating Scale
Tidsramme: Baseline and at 18 months (or at the time of discontinuation)
A severity of PD symptom are assessed by Modified Hoehn & Yahr rating scale. This scale consist of 10 levels including additional evaluation levels defined in Japan. Ten levels are described by 0 (best), 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5 (worst).
Baseline and at 18 months (or at the time of discontinuation)

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Boehringer Ingelheim

Publikationer og nyttige links

Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.

Hjælpsomme links

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart

1. februar 2004

Primær færdiggørelse (Faktiske)

1. marts 2009

Datoer for studieregistrering

Først indsendt

31. januar 2008

Først indsendt, der opfyldte QC-kriterier

13. februar 2008

Først opslået (Skøn)

14. februar 2008

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Skøn)

11. juli 2014

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

10. juni 2014

Sidst verificeret

1. juni 2014

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • 248.547

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Parkinsons sygdom

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Saudi Arabia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner